Comment by refurb

That’s not how drug approvals work. You don’t make assumptions about safety, you make decisions based on data.

The original trials were for a specific population - no prior HPV infection, young women. Hence the approval was for that population.

Additional trials have been run expanding the population, but the decision was based on data not “yeah, I’ll bet this is safe/works for this other group”